Marianne Zhen Biography and Net Worth

CAO of Innoviva

Marianne Zhen joined Innoviva in October 2014. Prior to joining Innoviva, Ms. Zhen served as the Corporate Controller at Steelwedge Software Inc. from 2012 to 2014, Intelmate from 2011 to 2012 and Model N, Inc. from 2007 to 2011. Previously, Ms. Zhen served as a member of the board of directors of CalCPA Peninsula Silicon Valley Chapter. Ms. Zhen earned a Bachelor of Science degree in Business Administration with a concentration in Accounting from San Francisco State University. She is a member of the American Institute of Certified Public Accountants (AICPA) and a member of California Society of Certified Public Accountants (CalCPA).

What is Marianne Zhen's net worth?: The estimated net worth of Marianne Zhen is at least $556,883.18 as of August 19th, 2021. Ms. Zhen owns 36,493 shares of Innoviva stock worth more than $556,883 as of April 26th. This net worth evaluation does not reflect any other investments that Ms. Zhen may own. Additionally, Ms. Zhen receives an annual salary of $530,210.00 as CAO at Innoviva. Learn More about Marianne Zhen's net worth.
How old is Marianne Zhen?: Ms. Zhen is currently 55 years old. There are 2 older executives and no younger executives at Innoviva. The oldest executive at Innoviva is Mr. Stephen Basso M.B.A., Chief Financial Officer, who is 58 years old. Learn More on Marianne Zhen's age.
What is Marianne Zhen's salary?: As the CAO of Innoviva, Inc., Ms. Zhen earns $530,210.00 per year. The highest earning executive at Innoviva is Mr. Pavel Raifeld C.F.A., Chief Executive Officer, who commands a salary of $754,670.00 per year. Learn More on Marianne Zhen's salary.
How do I contact Marianne Zhen?: The corporate mailing address for Ms. Zhen and other Innoviva executives is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. Innoviva can also be reached via phone at (650) 238-9600 and via email at [email protected]. Learn More on Marianne Zhen's contact information.
Has Marianne Zhen been buying or selling shares of Innoviva?: Marianne Zhen has not been actively trading shares of Innoviva in the last ninety days. Most recently, Marianne Zhen sold 2,802 shares of the business's stock in a transaction on Thursday, August 19th. The shares were sold at an average price of $16.02, for a transaction totalling $44,888.04. Following the completion of the sale, the chief accounting officer now directly owns 36,493 shares of the company's stock, valued at $584,617.86. Learn More on Marianne Zhen's trading history.
Who are Innoviva's active insiders?: Innoviva's insider roster includes George Bickerstaff, III (Director), and Marianne Zhen (CAO). Learn More on Innoviva's active insiders.
Are insiders buying or selling shares of Innoviva?: During the last year, Innoviva insiders bought shares 5 times. They purchased a total of 517,000 shares worth more than $6,539,080.00. The most recent insider tranaction occured on June, 5th when Major Shareholder Alexander J Denner bought 7,000 shares worth more than $91,280.00. Insiders at Innoviva own 1.4% of the company. Learn More about insider trades at Innoviva.
Information on this page was last updated on 6/5/2023.

Marianne Zhen Insider Trading History at Innoviva

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/19/2021	Sell	2,802	$16.02	$44,888.04	36,493
2/26/2019	Sell	5,617	$16.00	$89,872.00

Marianne Zhen Buying and Selling Activity at Innoviva

Innoviva Company Overview

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Today's Range

Now: $15.26

$15.01

$15.29

50 Day Range

MA: $15.02

$14.40

$15.86

2 Week Range

Now: $15.26

$11.37

$16.86

Volume

415,799 shs

Average Volume

674,342 shs

Market Capitalization

$964.84 million

P/E Ratio

7.00

Dividend Yield

N/A

Beta

0.57

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

Marianne Zhen Biography and Net Worth

What is Marianne Zhen's net worth?

How old is Marianne Zhen?

What is Marianne Zhen's salary?

How do I contact Marianne Zhen?

Has Marianne Zhen been buying or selling shares of Innoviva?

Who are Innoviva's active insiders?

Are insiders buying or selling shares of Innoviva?